Apollo Global Management in Talks to Acquire J&J's DePuy Synthes Unit

Apollo Eyes $15 Billion J&J Orthopedics Unit

Apollo Global Management is reportedly in advanced discussions to acquire Johnson & Johnson's DePuy Synthes orthopedics unit, with a potential deal value estimated at $15 billion. The divestiture aligns with $JNJ's ongoing strategy to streamline its portfolio, following the spin-off of its consumer health business, Kenvue, in 2023. This move would significantly bolster Apollo's presence in the medical device sector.

Shares of Johnson & Johnson ($JNJ) opened higher by 0.8% at $158.20 on Tuesday, indicating a positive market reaction to the potential for a more focused, higher-growth enterprise. Conversely, Apollo Global Management ($APO) saw its stock decline by 1.2% to $104.55, as investors considered the financing implications of such a substantial acquisition. Trading volumes for both companies were notably elevated, with $JNJ seeing 1.5 times its 30-day average volume in the first hour.

Market Impact

The news of a potential DePuy Synthes sale marks a significant step in Johnson & Johnson's transformation, which began with the separation of Kenvue ($KVUE) in August 2023, valued at approximately $40 billion. This latest divestiture would further solidify $JNJ's identity as a pharmaceutical and innovative medical technology powerhouse, moving away from more mature, capital-intensive product lines. The implied $15 billion valuation for DePuy Synthes suggests a multiple of roughly 3x its estimated 2023 sales of $5 billion, a premium compared to some recent med-tech divestitures.

For Apollo Global Management ($APO), the acquisition of a unit the size of DePuy Synthes would be one of its largest healthcare investments to date, significantly expanding its $470 billion assets under management. The initial 1.2% decline in $APO's stock reflects investor scrutiny over the debt financing likely required for a deal of this magnitude, which could temporarily impact its balance sheet. However, a successful integration and operational improvements could yield substantial returns, given Apollo's track record in private equity turnarounds.

The broader medical device sector, as tracked by the iShares U.S. Medical Devices ETF ($IHI), saw a modest uptick of 0.3% following the reports. This suggests that while the specific deal is company-centric, it also signals a healthy M&A environment within healthcare, potentially encouraging other large players to divest non-core assets. Competitors within orthopedics, such as Stryker ($SYK) and Zimmer Biomet ($ZBH), could face increased competitive pressure from an independent, private equity-backed DePuy Synthes focused on growth.

What Analysts Are Saying

"This potential divestiture is a clear positive for Johnson & Johnson ($JNJ), further sharpening its strategic focus on higher-margin pharmaceutical and innovative medical technology segments," commented Citi analyst Joanne Wu. "We believe the market is rewarding $JNJ for its disciplined portfolio management, potentially leading to an upward revision of our $165 price target, contingent on the final deal terms and valuation." Wu noted that shedding DePuy Synthes, with its complex supply chains and intense competition, could unlock greater agility for $JNJ's remaining divisions.

Morgan Stanley's healthcare team expressed a more nuanced view regarding Apollo Global Management ($APO). "While the acquisition of DePuy Synthes presents a compelling opportunity for Apollo to gain a leadership position in a critical medical device segment, the financing structure will be key," stated lead analyst David Wilson. "We estimate Apollo may need to raise $10-$12 billion in debt, which could pressure near-term earnings per share. However, if they can execute operational improvements and market expansion efficiently, this could be a long-term value creator, potentially adding $5-$7 per share to our $APO sum-of-the-parts valuation over five years."

Jefferies analyst Ken Mak also weighed in, highlighting the broader M&A implications. "This deal, if finalized, underscores the robust appetite for quality assets within the healthcare sector, particularly from private equity firms seeking stable, cash-generative businesses," Mak wrote in a client note. "It could catalyze a wave of similar divestitures from diversified healthcare conglomerates looking to optimize their portfolios, potentially driving further M&A activity in late 2024 and early 2025 across medical devices and diagnostics."

What to Watch

Investors should closely monitor the official announcement from Johnson & Johnson ($JNJ) and Apollo Global Management ($APO), which could detail the final transaction value, financing structure, and expected closing timeline. Any definitive agreement is anticipated to be announced within the next few weeks, potentially by late September 2024.

Regulatory approvals will be a critical hurdle, particularly from the U.S. Federal Trade Commission (FTC) and European Union competition authorities. Given DePuy Synthes' significant market share in certain orthopedic segments, antitrust reviews could extend the closing period, potentially pushing it into Q1 2025. Any signs of regulatory pushback could introduce uncertainty and pressure both $JNJ and $APO shares.

Apollo's upcoming Q3 2024 earnings call, tentatively scheduled for late October, will provide an opportunity for management to elaborate on the strategic rationale and financing plan for the DePuy Synthes acquisition. Key metrics to watch include any updates on $APO's leverage ratios and future capital deployment strategies. For $JNJ, its next investor day or quarterly earnings call will be crucial for understanding its capital allocation plans post-divestiture, including potential share buybacks or increased dividends.